Preliminary Program

  • Tailored radiotherapy: Dose and schedule
  • HER2 targeted therapy: What, when and for how long?
  • Can we avoid over or undertreatment of DCIS?
  • When is the optimal time to integrate palliative care?
  • Who is the right candidate for neoadjuvant therapy?
  • The changing landscape of breast imaging for screening and diagnosis
  • Rethinking trial design
  • Can screening and prevention be integrated and personalized?
  • When can targeted therapies replace chemotherapy?
  • Optimizing choices for mastectomy and reconstruction
  • Should oligometastatic disease be treated with curative intent?
  • The extent/intensity of endocrine therapy: Balancing efficacy with quality of life
Skip to content